A thorough understanding of how these inhibitors affect FAK or PYK2 function may also allow testing their efficacy in other pathologies implicating FAK or PYK2, such as neurodegenerative diseases [231,232,233]. This evidence concerns the gene PTK2 and neurodegenerative disease.